title: Erectile dysfunction after kidney transplantation: our 22 years of experience.
abstract: OBJECTIVE
  To evaluate the results of treatment of erectile dysfunction (ED) in kidney transplant recipients before and after the advent of sildenafil.
  
  
  METHODS
  From 1981 through 2002, 971 male patients of mean age 53.4 years received a renal graft. Erectile dysfunction (ED) was investigated in all patients at the first urologic visit posttransplantation. Psycho-sexual support was offered to all patients. Before sildenafil use (1998), our diagnostic approach was complex. From 1998 we tested: serum levels of testosterone, prolactin, and glucose with penile duplex ultrasonography and NPT reserved for selected cases.
  
  
  RESULTS
  From 1981 through 1998, 365 male kidney transplant recipients (45%) reported ED. Only 169 patients chose to be treated: 27 responded to psycho-sexual therapy; 3 received testosterone with benefit; 133 had a good results from intracavernosal injection of vasoactive drugs; and 6 received a penile prosthesis. Since 1998, 126 patients reported ED (78.3%). Only 78 chose treatment: 24 patients had a satisfactory response to sildenafil (65% with 50 mg and 35% with 100 mg). PGE1 alone or in combination with papaverine and phentolamine produced a good response in 37 patients; 17 patients did not respond to pharmacotherapy; and 5 received a tricomponent penile prosthesis without complications. The side effects of sildenafil and PGE1 therapy were similar to those reported in the literature.
  
  
  CONCLUSIONS
  ED is an important problem in male renal transplant recipients. Cultural resistance to treatment is common. However, treatment with sildenafil citrate and intracavernosal self-injection of PGE1 are well accepted, and prosthetic devices may help in resistant cases.
authors.affiliation: Dipartimento di Nefro-Urologia, Ospedale Molinette, ASO san Giovanni Battista della città di Torino, Torino, Italy.
authors.forename: F
authors.initials: F
authors.lastname: Lasaponara
authors.forename: M
authors.initials: M
authors.lastname: Paradiso
authors.forename: M G L
authors.initials: MG
authors.lastname: Milan
authors.forename: F
authors.initials: F
authors.lastname: Morabito
authors.forename: O
authors.initials: O
authors.lastname: Sedigh
authors.forename: M E
authors.initials: ME
authors.lastname: Graziano
authors.forename: A
authors.initials: A
authors.lastname: Abbona
authors.forename: G B
authors.initials: GB
authors.lastname: Piccoli
authors.forename: M
authors.initials: M
authors.lastname: Rossetti
authors.forename: E
authors.initials: E
authors.lastname: Mezza
authors.forename: U
authors.initials: U
authors.lastname: Ferrando
mesh_terms: D007172:Erectile Dysfunction / Q000453:epidemiology / Q000209:etiology* / Q000517:prevention & control; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications; D016030:Kidney Transplantation / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use; D011687:Purines; D012189:Retrospective Studies; D000068677:Sildenafil Citrate; D013450:Sulfones; D014665:Vasodilator Agents / Q000627:therapeutic use
chemical_list: D010879:Piperazines; D011687:Purines; D013450:Sulfones; D014665:Vasodilator Agents; D000068677:Sildenafil Citrate